ID   OVCAR-3/TxT5
AC   CVCL_DA02
SY   OVCAR-3TxT5
DR   cancercelllines; CVCL_DA02
DR   GEO; GSM95456
DR   Progenetix; CVCL_DA02
DR   Wikidata; Q54937009
RX   PubMed=16382445;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0465 ! OVCAR-3
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 13
//
RX   PubMed=16382445; DOI=10.1002/gcc.20300;
RA   Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K.,
RA   Chen X., Sikic B.I.;
RT   "Regional activation of chromosomal arm 7q with and without gene
RT   amplification in taxane-selected human ovarian cancer cell lines.";
RL   Genes Chromosomes Cancer 45:365-374(2006).
//